AsymBio Secures $184 Million to Expand Global CDMO Growth
Shanghai, China, August 4, 2026 AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Shanghai, China, August 4, 2026 AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem...
Phoenix, Arizona, August 3, 2026 BioLab Holdings, Inc. has announced the publication of a peer-reviewed real-world evidence (RWE) study...
